Abstract

For the last 10 years, applying new sequencing technologies to thousands of whole exomes has revealed the high variability of the human genome. Extreme caution should thus be taken to avoid misinterpretation when associating rare genetic variants to disease susceptibility. The Brugada syndrome (BrS) is a rare inherited arrhythmia disease associated with high risk of sudden cardiac death in the young adult. Familial inheritance has long been described as Mendelian, with autosomal dominant mode of transmission and incomplete penetrance. However, all except 1 of the 23 genes previously associated with the disease have been identified through a candidate gene approach. To date, only rare coding variants in the SCN5A gene have been significantly associated with the syndrome. However, the genotype/phenotype studies conducted in families with SCN5A mutations illustrate the complex mode of inheritance of BrS. This genetic complexity has recently been confirmed by the identification of common polymorphic alleles strongly associated with disease risk. The implication of both rare and common variants in BrS susceptibility implies that one should first define a proper genetic model for BrS predisposition prior to applying molecular diagnosis. Although long remains the way to personalized medicine against BrS, the high phenotype variability encountered in familial forms of the disease may partly find an explanation into this specific genetic architecture.

Highlights

  • The Brugada syndrome (BrS) is a rare inherited arrhythmia disease, first described in 1992, increasing the risk of ventricular fibrillation in apparently healthy young adults [1]

  • Combined to the availability of the reference assembly of the human genome [77, 78], next-generation sequencing (NGS)-based approaches have revealed the high variability of the human genome, with at least 300–600 functional genetic variants detected in each exome [75] – and has retrospectively changed the interpretation of previous rare variants identified by candidate gene approach

  • We have investigated the cosegregation of SCN5A mutations with BrS among large genotyped families [41]

Read more

Summary

INTRODUCTION

The Brugada syndrome (BrS) is a rare inherited arrhythmia disease, first described in 1992, increasing the risk of ventricular fibrillation in apparently healthy young adults [1]. Implantation of a defibrillator is still the only efficient therapy in high-risk patients, with a 48% rate of appropriate device therapy at 10 years in patients with previous aborted sudden death. This rate falls to 12% among implanted asymptomatic patients, many affected patients remaining asymptomatic during all their life. Device-related complications are frequent with a 30% risk at 10-year follow-up mainly due to lead dysfunction, inappropriate therapy, and infection [18, 19] These serious side effects in comparison to the very low arrhythmic risk for asymptomatic patients require accurate risk stratification and/ or efficient drug therapy. Many clinical parameters have been proposed for asymptomatic patients, but risk prediction in the latter group of patients remains challenging because of the lack of reproducible and reliable data [28]

TWO PATHOPHYSIOLOGICAL MODELS FOR BrS
FROM A FAMILIAL DISEASE TO THE IDENTIFICATION OF RARE VARIANTS
LIMITS IN INTERPRETING RARE VARIANTS CARRIED BY PATIENTS WITH BrS
Functional effect of the mutation
Findings
CONCLUSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call